Reni Benjamin
Stock Analyst at Citizens
(1.29)
# 3,687
Out of 5,132 analysts
162
Total ratings
36.03%
Success rate
-16.45%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.80 | +177.78% | 9 | Jan 9, 2026 | |
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $6.28 | +59.24% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $5.24 | +129.01% | 15 | Oct 31, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $75.80 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.31 | +549.25% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.15 | +566.67% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $101.10 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $6.91 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $0.65 | +512.00% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.65 | +142.42% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.13 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.48 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $16.09 | -37.85% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $23 | $16.16 | +42.33% | 11 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.85 | +29.87% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $8.31 | +236.94% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.07 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $14.96 | +167.38% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.57 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.23 | +79.37% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.48 | -15.61% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $45.25 | +32.60% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.60 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $144.42 | +118.11% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $69.99 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $248.35 | +6.70% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.40 | +400.00% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $7.99 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.71 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $28.50 | -57.89% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.10 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Jan 9, 2026
Upgrades: Market Outperform
Price Target: $5
Current: $1.80
Upside: +177.78%
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $6.28
Upside: +59.24%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $5.24
Upside: +129.01%
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $75.80
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.31
Upside: +549.25%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.15
Upside: +566.67%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $101.10
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.91
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $0.65
Upside: +512.00%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.65
Upside: +142.42%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.13
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.48
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $16.09
Upside: -37.85%
Jan 20, 2026
Upgrades: Market Outperform
Price Target: $23
Current: $16.16
Upside: +42.33%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.85
Upside: +29.87%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $8.31
Upside: +236.94%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.07
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $14.96
Upside: +167.38%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.57
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.23
Upside: +79.37%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.48
Upside: -15.61%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $45.25
Upside: +32.60%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.60
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $144.42
Upside: +118.11%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $69.99
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $248.35
Upside: +6.70%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.40
Upside: +400.00%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $7.99
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.71
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $28.50
Upside: -57.89%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $20.10
Upside: -